Transcatheter Aortic Valve Replacement Update in Bicuspid Aortic Valve Disease
‘Transcatheter aortic valve replacement update in bicuspid aortic valve disease’ brings together four international opinion leaders to comprehensively review the latest clinical evidence, evaluate recent trial outcomes, address patient and device selection, and provide practical insight through case reviews.
Designed to best support both cardiologists and surgeons, this engaging one-hour educational programme will be further enhanced through a live Q&A session, to help address some of the most pertinent and challenging questions in clinical practice.
Nicolas M Van Mieghem
This webinar is supported by:
Welcome, introduction to the topic – Prof Van Mieghem, Chair
TAVR in low risk bicuspid patients: critical review of the clinical evidence – Dr Ramlawi
Implant techniques and device selections for bicuspid patients – Presentation by Dr Tchetche
TAVR in bicuspid patients: case reviews – Prof Zahr
Discussion and live Q&A – All, moderated by Prof Van Mieghem
- Describe the latest data in bicuspid valve disease and understand the classifications
- Critically evaluate clinical trial data in TAVR in low-risk bicuspid patients
- Review implant techniques and device considerations for bicuspid patients
- This programme has been formulated to best support the learnings of cardiologists and surgeons globally.
Nicolas M Van Mieghem
From an early age, Professor Nicolas Maria Van Mieghem decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them. I wanted to enter a profession that would channel my energy— I was always a busy child,” he says.
A budding athlete, he was a member of Belgium’s national swimming team but soon realized that medicine was his true calling. His father was a general cardiologist and one of his biggest influences early in his career.
Professor Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002.
His mantra is mens sana in corpore sano (a healthy mind in a healthy body). He remains an avid swimmer and cyclist and follows a number of professional sports. “Like all Belgians, I love to watch the big cycling events—the classic cycle races, the Tour de France, the Giro d’Italia, the Vuelta a España,” he says.
Van Mieghem believes that a great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
In 2007, Professor Van Mieghem obtained his medical and cardiology degrees at the Catholic University of Leuven, Belgium. He completed fellowships in interventional cardiology in Ziekenhuis Oost-Limburg Genk, Belgium, Lenox Hill Hospital, New York, US and Erasmus Medical Center, Rotterdam, the Netherlands.2 His PhD focused on transcatheter valve therapies.3
His current research focuses on cerebral embolic protection during TAVI and the search for improved large bore closure devices. He works actively in expanding TAVI indications, most notably TAVI as a means to further unload the left ventricle in heart failure patients with moderate aortic stenosis (the TAVR UNLOAD trial). Professor Van Mieghem is also involved in the development and dispersion of mechanical circulatory support (MCS) devices as well as transcatheter mitral and tricuspid repair techniques. In terms of imaging and preprocedural planning, his research has covered computed tomography (CT)-derived 3D modelling and printing.
Professor Van Mieghem has received institutional research grant support from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Medtronic, Daiichi-Sankyo, PulseCath BV and Abiomed.7
After his fellowships, Professor Van Mieghem joined the department of interventional cardiology at the Thorax Centre, Erasmus Medical Center, as a senior staff member in February 2010. He is now working there as a Full Professor of Interventional Cardiology.2
As well as his involvement in the percutaneous coronary interventions and structural heart programs, he has published and co-authored over 350 scientific papers in peer-reviewed journals.4 Professor Van Mieghem is a principal investigator and steering committee member in multiple ongoing international trials, evaluating various coronary and transcatheter valve technologies.3 He is a Fellow of the European Society of Cardiology (FESC) and is currently Medical Director of the department of Interventional cardiology at the Thorax Centre.3
- 2008 - 2009: Fellow, Interventional Cardiology, Lenox Hill Hospital
- 2010: Joined the senior staff, Interventional Cardiology, Thorax Centre, Erasmus MC
- 2014: Clinical Director, Interventional Cardiology, Erasmus MC
- 2019 - Present: Full Professor, Interventional Cardiology, Erasmus MC
- Present: Medical Director, Interventional Cardiology, Thorax Centre
Areas of Speciality4
- Interventional Cardiology
- Transcatheter Heart Valve Interventions
Prof Van Mieghem is on the ICR3 Editorial Board.
Valley Health System, Virginia, US
Didier Tchétché, (Clinique Pasteur, Toulouse, France) Graduated from the University of Paris V where Dr Tchétché obtained his post-graduate diploma of cardiovascular pathology in 2004. From 2004 to 2005, he completed a 12-month fellowship period in the Hemodynamic and Interventional Cardiology department of Clinique Pasteur in Toulouse and from 2005 to 2007 he was Head Assistant at the intensive care unit of Bichât Hospital in Paris.
In 2008, he joined the interventional cardiovascular group in Clinique Pasteur, Toulouse, and he is currently Head of the Structural programme with an experience of more than 5000 TAVI procedures. His main areas of interest are coronary interventions and valvular heart disease. He has been actively involved in many clinical trials involving new technologies and devices in the field of interventional cardiology.
Oregon Health and Science University, US